Clinical Research Directory

Inclusion Criteria: * newly-diagnosed supratentorial glioblastoma, IDH-wildtype, WHO grade 4 * male or female adult patients \< 70 years old * Karnofsky performance status (KPS) score higher or equal to 60 * a minimum life expectancy of 12 weeks * adequate bone marrow function (white blood cell ≥ 2.0 × 10\^9/L, neutrophils ≥ 1.5 × 10\^9/L, hemoglobin ≥ 90 g/L, and platelets ≥ 100 × 10\^9/L) * adequate hepatic function (direct bilirubin and indirect bilirubin ≤ 1.5 mg/dL, and alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\] \< 4 times the upper limit of normal) * adequate renal function (creatinine \< 80 umol/L) * adequate coagulation function (international normalized ratio \[INR\] ≤ 1.3) * voluntary to participate in this trial, complete all pre-specified treatment regimens, and complete required follow-up Exclusion Criteria: * unwilling to participate or accept the pre-specified treatment regimen and required follow-up schedule * prior treatment (surgery, radiotherapy, chemotherapy) for glioblastoma * pregnant or lactating patients * allergic to Elemene and its components * severe liver and kidney dysfunction, coagulation disorders, or decreased hematopoietic ability * serious infection * serious hyperlipidaemia * medical illness or psychosocial circumstance that may compromise participant safety